Non-steroidal anti-inflammatory drugs frequently cause adverse reactions. This retrospective study was based on analysis of the data obtained from interviews conducted with 173 patients, who underwent and tolerated a challenge test with etoricoxib (a selective cyclooxigenase 2 enzyme inhibitor). Only one of 82 patients who were treated with etoricoxib reported reactions. We can conclude that etoricoxib shows a high long-term tolerability in patients with non-steroidal anti-inflammatory drug hypersensitivity.
SzczeklikAGryglewskiRJCzerniawska-MysikG. Clinical patterns of hypersensitivity to non-steroidal anti-inflammatory drugs and their pathogenesis. J Allergy Clin Immunol1977; 60:276–84.
2.
QuiralteJBlancoCCastilloRDelgadoJCarrilloT. Intolerance to non-steroidal anti-inflammatory drugs: results of controlled drug challenges in 98 patients. J Allergy Clin Immunol1996; 98:678–85.
3.
JohanssonSGBieberTDahlR. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol2004; 113:832–6.
4.
AseroR. Etoricoxib challenge in patients with chronic urticaria with NSAID intolerance. Clin Exp Dermatol2007; 32:661–3.
5.
NettisEDi PaolaRFerranniniATursiA. Tolerability of rofecoxib in patients with cutaneous adverse reactions to non-steroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol2002; 88:331–4.
6.
NettisEColanardiMCFerranniniATursiA. Short-term and long-term tolerability of rofecoxib in patients with prior reactions to non-steroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol2005; 94:29–33.
7.
ColanardiMCNettisETraettaPDaprileCFittoCAloiaAMDi LeoEFerranniniAVaccaA. Safety of parecoxib in patients with non-steroidal anti-inflammatory drug-induced urticaria or angioedema. Ann Allergy Asthma Immunol2008; 100:82–5.
8.
El MiedanyYYoussefSAhmedIEl GaafaryM. Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol2006; 97:105–9.
